Containment FDA Approval Hormones Nurses 
Pfizer
JANUARY 27, 2023
In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells. A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir.
The Pharma Data
JUNE 18, 2021
IMBRUVICA is the only FDA-approved medicine in WM and cGVHD. IMBRUVICA was one of the first medicines to receive FDA approval via the Breakthrough Therapy Designation pathway. Concomitant use of preparations containing?St. Advise nursing women to discontinue breastfeeding during treatment. John’s?wort
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
AUGUST 11, 2020
1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Institute hormone replacement therapy for endocrinopathies as warranted.
The Pharma Data
JUNE 18, 2021
IMBRUVICA is the only FDA-approved medicine in WM and cGVHD. IMBRUVICA was one of the first medicines to receive FDA approval via the Breakthrough Therapy Designation pathway. Concomitant use of preparations containing St. Advise nursing women to discontinue breastfeeding during treatment. November 2020.
The Pharma Data
AUGUST 11, 2020
1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Institute hormone replacement therapy for endocrinopathies as warranted.
Expert insights. Personalized for you.
112 
Let's personalize your content